Nexentis Technologies Inc. (NXTS): EPS (Diluted)
-$8.61
Year ended 2025-12-31
| Period ended | EPS (Diluted) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$8.61 | n/m | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | -$27.74 | n/c | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | -$5.43 | n/c | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $10.85 | n/a | 2024-04-01, From 2022-01-01 |
EPS (Diluted) at similar companies
| Company | Year ended | EPS (Diluted) | Change YoY |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | -$8.61 | n/m |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $0.00 | n/m |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | -$0.06 | n/m |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | -$0.39 | n/m |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | -$1.40 | n/m |
| Galectin Therapeutics Inc (GALT) | 2025-12-31 | -$0.48 | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$0.12 | n/m |
| Phio Pharmaceuticals Corp. (PHIO) | 2024-12-31 | -$9.08 | n/m |
| Lftd Partners Inc. (LIFD) | 2025-12-31 | -$1.68 | n/m |
Compare NXTS, EVFM, MENS, ABVC side by side · Screen every company in Pharmaceutical Preparations ↗